Who
Michael Burkes Brophy
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Natera.
In numbers
- Trades disclosed
- 623
- Buys
- 0
- Sells
- 184
- Bought
- $0
- Sold
- $103.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 9 Jun 2017
- Last trade
- 4 Aug 2026
- Last filed
- 5 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 2 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Aug 2026filed 5 Aug 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $131K478 at $274.22 | filing |
| 4 Aug 2026filed 5 Aug 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $131K478 at $274.22 | filing |
| 3 Aug 2026filed 5 Aug 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $85K317 at $267.99 | filing |
| 3 Aug 2026filed 5 Aug 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $85K317 at $267.99 | filing |
| 29 Jul 2026filed 29 Jul 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $465K1,863 at $249.38 | filing |
| 29 Jul 2026filed 29 Jul 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $465K1,863 at $249.38 | filing |
| 28 Jul 2026filed 29 Jul 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $315K1,241 at $254.07 | filing |
| 28 Jul 2026filed 29 Jul 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $256K1,008 at $253.77 | filing |
| 28 Jul 2026filed 29 Jul 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $43K170 at $254.33 | filing |
| 28 Jul 2026filed 29 Jul 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $315K1,241 at $254.07 | filing |
| 28 Jul 2026filed 29 Jul 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $256K1,008 at $253.77 | filing |
| 28 Jul 2026filed 29 Jul 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $43K170 at $254.33 | filing |
| 27 Jul 2026filed 29 Jul 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $204K782 at $260.49 | filing |
| 27 Jul 2026filed 29 Jul 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $204K782 at $260.49 | filing |
| 4 May 2026filed 5 May 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $101K482 at $210.49 | filing |
| 4 May 2026filed 5 May 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $101K482 at $210.49 | filing |
| 1 May 2026filed 5 May 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $65K313 at $206.16 | filing |
| 1 May 2026filed 5 May 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $65K313 at $206.16 | filing |
| 29 Apr 2026filed 29 Apr 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $57K300 at $190.12 | filing |
| 29 Apr 2026filed 29 Apr 2026 | NTRA NateraDiagnostics & Labs | SEC FORM 4 Sold | $96K500 at $192.13 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Financial Comparison: Valneva (NASDAQ:VALN) and Natera (NASDAQ:NTRA)NTRA · tickerreport.com · 22 Oct 2026Natera (NTRA) Is Expanding Cancer Testing Rapidly. Does Its Valuation Leave Room for Error?NTRA · insidermonkey.com · 20 Oct 2026ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology | wallstreetONLINENTRA · wallstreet-online.de · 19 Oct 2026
0 headlines in the last 90 days name Michael Burkes Brophy; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.